BPRG Bioprogress

RNS Number:2058C
BioProgress PLC
16 August 2007


For Immediate Release                                             16 August 2007

                                BioProgress Plc

                   Approval for SoluPol(TM) enabled Hypozalix(TM)

London UK, 16 August 2007, BioProgress (AIM: BPRG), the specialty pharmaceutical
and healthcare company announces the gaining of Medical Device approvals from an
EU Notified Body for two novel line extensions of the Artisial / Hypozalix(TM)
brand using SoluPol(TM) technology.

This regulatory approval equates to authorisation to sell the products to the
general public in Europe and certain other markets such as South America and the
Middle East. The endorsement also represents a further validation of the core
enabling technology of the Group.

Artisial / Hypozalix(TM) is BioProgress' proprietary product for the treatment
of xerostomia (dry mouth). The two new formulations are a liquid mouthwash and
oral gel designed to re-hydrate the oral mucosa. This range compliments the
existing oral spray product and fits within the Group's sore mouth franchise.
The range allows BioProgress to compete more effectively in salvia replacement
market with planned extension into the oral healthcare market.

Xerostomia, the first indication, is a dry mouth condition caused by a lack of
production of saliva. It is estimated to affect between 10 and 24 per cent of
the adult population and up to as much as 46 per cent of elderly people. It is
also disease related and is often a known side effect of drug therapy. In
addition to the two new Hypozalix products, the new approved formulations
together with the originator sprays will be marketed by Melbrosin, the OTC
division of the Group. This marketing initiative will utilize the Menoflavon
brand, targeting xerostomia associated with menopausal symptoms. The product
will be made available for the whole of the existing Menoflavon distribution
system.

The line, brand and range extensions approved for marketing will be available
both as prescription as well as over the counter medicines. It is expected these
will be launched in Q4 2007.

Steve Martin, Chief Development Officer, BioProgress said: "The approval of two
new line extensions using our polymer technology is clear validation that
BioProgress is able to take products from concept through to market. The
integration between the different sites has gone smoothly as evidenced by the
Melbrosin division being able to launch products from our development pipeline."


Richard Trevillion, Chief Executive Officer, BioProgress said: "Once again this
accreditation demonstrates the strength of the Company's development pipeline.
We are continually proving our ability to apply our enabling technologies to
make products that reach the market and are able to deliver revenues which
further increase shareholder value."


For further information:

BioProgress Plc                                            + 44 (0) 20 7098 9881
Richard Trevillion, CEO
Steve Martin, CDO

Hiral Patel, CFO
Buchanan Communications                                    + 44 (0) 20 7466 5000
Rebecca Skye Dietrich
Mark Court

About BioProgress

BioProgress plc is an innovative specialty pharmaceutical and healthcare
business based around its platform technologies in polymer and film systems.
Listed on London's AIM in May 2003, the company has over 80 patents granted or
in application within 24 patent families and has product development agreements
and strategic alliances with several global companies. As a virtually integrated
business, BioProgress has acquired sales and marketing resources within Europe
and the US as a launch mechanism for its own pharmaceutical and healthcare
products. The business continues to develop innovative delivery mechanisms using
its XGEL(TM) polymer technology. For further information please go to
www.bioprogress.com






                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

MSCSFLEDISWSEEA

Bioprogress (LSE:BPRG)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024

Bioprogress (LSE:BPRG)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024